Hologic, Inc. (NASDAQ:HOLX) Shares Bought by Exchange Traded Concepts LLC

Exchange Traded Concepts LLC lifted its position in shares of Hologic, Inc. (NASDAQ:HOLX) by 5.7% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 20,764 shares of the medical equipment provider’s stock after purchasing an additional 1,115 shares during the period. Exchange Traded Concepts LLC’s holdings in Hologic were worth $1,497,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in HOLX. Wolff Wiese Magana LLC purchased a new position in shares of Hologic in the 3rd quarter worth about $25,000. General Partner Inc. purchased a new position in Hologic in the fourth quarter valued at approximately $26,000. Groupama Asset Managment lifted its position in Hologic by 9.9% during the third quarter. Groupama Asset Managment now owns 33,177 shares of the medical equipment provider’s stock valued at $27,000 after buying an additional 2,999 shares in the last quarter. Sunbelt Securities Inc. purchased a new stake in Hologic during the second quarter worth approximately $37,000. Finally, First Horizon Advisors Inc. increased its position in shares of Hologic by 38.3% in the third quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider’s stock worth $39,000 after acquiring an additional 134 shares in the last quarter. Institutional investors and hedge funds own 94.73% of the company’s stock.

Hologic Stock Performance

Hologic stock opened at $72.81 on Tuesday. The company has a market cap of $16.43 billion, a PE ratio of 21.86, a P/E/G ratio of 2.43 and a beta of 0.97. Hologic, Inc. has a 12 month low of $68.61 and a 12 month high of $84.67. The company has a fifty day moving average price of $73.89 and a two-hundred day moving average price of $78.25. The company has a debt-to-equity ratio of 0.49, a current ratio of 3.69 and a quick ratio of 3.03.

Hologic (NASDAQ:HOLX) last released its quarterly earnings data on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share for the quarter, hitting the consensus estimate of $1.01. The firm had revenue of $987.90 million for the quarter, compared to analyst estimates of $978.25 million. Hologic had a net margin of 19.59% and a return on equity of 19.79%. Hologic’s quarterly revenue was up 4.5% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.89 earnings per share. Research analysts expect that Hologic, Inc. will post 4.27 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the stock. Mizuho decreased their price target on shares of Hologic from $90.00 to $87.00 and set an “outperform” rating for the company in a research report on Tuesday, November 5th. Jefferies Financial Group initiated coverage on Hologic in a research report on Tuesday, December 10th. They issued a “hold” rating and a $85.00 target price for the company. Wolfe Research began coverage on Hologic in a report on Friday, December 13th. They set a “peer perform” rating on the stock. Morgan Stanley decreased their price target on Hologic from $84.00 to $82.00 and set an “equal weight” rating for the company in a report on Monday, January 13th. Finally, JPMorgan Chase & Co. lifted their price objective on shares of Hologic from $92.00 to $94.00 and gave the company an “overweight” rating in a research note on Tuesday, November 5th. Seven equities research analysts have rated the stock with a hold rating, nine have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $88.92.

Insider Activity at Hologic

In other Hologic news, COO Essex D. Mitchell sold 24,856 shares of the firm’s stock in a transaction on Wednesday, December 4th. The stock was sold at an average price of $76.34, for a total value of $1,897,507.04. Following the sale, the chief operating officer now directly owns 27,957 shares in the company, valued at approximately $2,134,237.38. This trade represents a 47.06 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 1.88% of the company’s stock.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.